Cidara Therapeutics (CDTX) Given a $15.00 Price Target by Cantor Fitzgerald Analysts

Cidara Therapeutics (NASDAQ:CDTX) has been given a $15.00 price objective by stock analysts at Cantor Fitzgerald in a research report issued to clients and investors on Friday. The firm currently has a “buy” rating on the biotechnology company’s stock. Cantor Fitzgerald’s target price would indicate a potential upside of 108.33% from the stock’s previous close.

The analysts wrote, “We are positive on Cidara ahead of Phase 2 CD101 IV data (STRIVE study) for the treatment of systemic infections in early to mid-March. Our estimate on the timing of data release stems from the fact that the last patient, last visit (LPLV) was last week.””

CDTX has been the topic of a number of other research reports. Zacks Investment Research lowered Cidara Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, January 12th. HC Wainwright upped their price objective on Cidara Therapeutics from $14.00 to $16.00 and gave the stock a “buy” rating in a report on Thursday, November 9th. One research analyst has rated the stock with a sell rating, two have given a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $12.93.

Cidara Therapeutics (NASDAQ:CDTX) remained flat at $$7.20 during trading hours on Friday. 35,400 shares of the company traded hands, compared to its average volume of 77,217. The firm has a market cap of $145.71 and a price-to-earnings ratio of -2.12. The company has a quick ratio of 7.69, a current ratio of 7.69 and a debt-to-equity ratio of 0.16. Cidara Therapeutics has a one year low of $5.60 and a one year high of $11.75.

Cidara Therapeutics (NASDAQ:CDTX) last announced its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.73) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.94) by $0.21. research analysts expect that Cidara Therapeutics will post -3.31 earnings per share for the current year.

In related news, major shareholder Target N. V. Biotech acquired 60,000 shares of Cidara Therapeutics stock in a transaction dated Wednesday, November 15th. The shares were acquired at an average cost of $7.57 per share, for a total transaction of $454,200.00. Following the completion of the transaction, the insider now directly owns 2,295,272 shares of the company’s stock, valued at $17,375,209.04. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 18.90% of the stock is owned by corporate insiders.

Institutional investors have recently added to or reduced their stakes in the stock. Citadel Advisors LLC acquired a new stake in Cidara Therapeutics during the second quarter worth about $129,000. Raymond James Financial Services Advisors Inc. acquired a new stake in Cidara Therapeutics during the second quarter worth about $131,000. OxFORD Asset Management LLP increased its stake in Cidara Therapeutics by 69.1% during the third quarter. OxFORD Asset Management LLP now owns 22,181 shares of the biotechnology company’s stock worth $187,000 after acquiring an additional 9,065 shares during the last quarter. JPMorgan Chase & Co. increased its stake in Cidara Therapeutics by 77.4% during the third quarter. JPMorgan Chase & Co. now owns 41,266 shares of the biotechnology company’s stock worth $328,000 after acquiring an additional 18,001 shares during the last quarter. Finally, Susquehanna International Group LLP acquired a new stake in Cidara Therapeutics during the second quarter worth about $350,000. Hedge funds and other institutional investors own 55.45% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/01/19/cidara-therapeutics-cdtx-buy-rating-reiterated-at-cantor-fitzgerald.html.

Cidara Therapeutics Company Profile

Cidara Therapeutics, Inc, formerly K2 Therapeutics, Inc, is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections.

Analyst Recommendations for Cidara Therapeutics (NASDAQ:CDTX)

Receive News & Ratings for Cidara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply